Novo Nordisk CEO Lars Fruergaard Jørgensen on Friday said the company’s experimental weight loss pill, amycretin, could eventually become a best-in-class treatment for obesity. The Danish drugmaker is racing to capitalize on the runaway success of its blockbuster weight loss drug Wegovy by developing a new generation of treatments for obesity, including more convenient and …
Continue reading “Weight reduction tablet might change into a best-in-class drug”